OncoMatch/Clinical Trials/NCT06844383
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Is NCT06844383 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Talazoparib with enzalutamide and Talazoparib for prostate cancer (adenocarcinoma).
Treatment: Talazoparib with enzalutamide · Talazoparib — The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: ATM pathogenic mutation
Required: ATR pathogenic mutation
Required: BRCA1 pathogenic mutation
Required: BRCA2 pathogenic mutation
Required: CDK12 pathogenic mutation
Required: CHEK2 pathogenic mutation
Required: FANCA pathogenic mutation
Required: MLH1 pathogenic mutation
Required: MRE11A pathogenic mutation
Required: NBN pathogenic mutation
Required: PALB2 pathogenic mutation
Required: RAD51C pathogenic mutation
Disease stage
Required: Stage IV
Metastatic disease required
Metastatic castration-resistant prostate cancer (mCRPC) as demonstrated by one of the following: Metastatic disease documented by conventional imaging...Measurable disease is not required.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: abiraterone acetate with prednisone (abiraterone acetate, prednisone) — mHSPC or locally advanced disease
Received prior abiraterone acetate with prednisone for mHSPC or locally advanced disease and on which progressed via a minimum of 2 rising PSA levels with a minimum of a 1-week interval between each determination or radiographic progression by any form of imaging
Cannot have received: androgen receptor pathway inhibitor (ARPI) other than abiraterone acetate with prednisone
Prior treatment for metastatic or non-metastatic CRPC with an ARPI other than abiraterone acetate with prednisone for ≥ 12 weeks
Cannot have received: PARP inhibitor
Prior treatment with a PARP inhibitor
Cannot have received: platinum-based chemotherapy
Prior platinum-based chemotherapy for the treatment of prostate cancer
Cannot have received: chemotherapy for castration-sensitive prostate cancer
Exception: chemotherapy completed >6 months prior to start of study treatment is allowed
Participants who received chemotherapy for castration-sensitive prostate cancer are still eligible provided chemotherapy was completed >6 months prior to start of study treatment
Cannot have received: investigational agents for the treatment of prostate cancer
Use of investigational agents for the treatment of prostate cancer within 4 weeks of start of study treatment
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500/µl; Hemoglobin ≥ 9g/dl; Platelet count ≥ 100,000/µl
Kidney function
Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN); Potassium ≥ 3.5 mmol/L (within institutional normal range)
Liver function
Bilirubin ≤ 1.3 x ULN (unless documented Gilbert's disease); AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN
Normal organ function with acceptable initial laboratory values within 14 days of treatment start: Absolute neutrophil count ≥ 1,500/µl; Hemoglobin ≥ 9g/dl; Platelet count ≥ 100,000/µl; Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN); Potassium ≥ 3.5 mmol/L (within institutional normal range); Bilirubin ≤ 1.3 x ULN (unless documented Gilbert's disease); AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana Farber Cancer Institute · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify